Is Phentermine a GLP-1? How the Two Drugs Differ
Is phentermine a GLP-1? No. The phentermine FDA label calls it a sympathomimetic amine. Its action is similar to amphetamine, and it is for a few weeks of use only. GLP-1 drugs such as semaglutide work on the GLP-1 receptor, part of the body's appetite system.
No head-to-head trial of the two was found. Also, phentermine alone is a different drug from the combination pill phentermine-topiramate. This page keeps those apart.
Short answer
- Is it a GLP-1?
- No. Phentermine is a sympathomimetic amine with activity similar to amphetamine. Semaglutide is a GLP-1 receptor agonist; tirzepatide acts on both GIP and GLP-1 receptors.
- How long it is used
- The phentermine label says short term, a few weeks. It is a Schedule IV controlled substance.
- Which loses more weight
- No head-to-head trial was found. The phentermine label says its extra loss over placebo was a fraction of a pound a week. A 2024 JAMA review pooled 11.4% for semaglutide.
Sources: Phentermine FDA label; Wegovy FDA label; Zepbound FDA label; JAMA 2024 review
What phentermine is, according to its label
In its label's words, phentermine is a "sympathomimetic amine anorectic". The label says it is used as a short-term add-on, for a few weeks, in a weight loss plan.
- The label says phentermine has activity similar to amphetamine, the prototype drug of its class.
- It says phentermine is only for short-term use, a few weeks, and on its own, for obesity.
- It is a Schedule IV controlled substance.
- The label also says it is not proven that these drugs work mainly by cutting appetite.
On dosing, the Sun Pharma phentermine FDA label states:
The usual adult dose is one tablet (37.5 mg) daily, as prescribed by the physician.
Disclaimer: this is label information, not a recommendation. Dose decisions belong with a licensed clinician. Other phentermine products may carry other strengths; only this label is cited here.
Sources: Phentermine FDA label
What makes a drug a GLP-1
A GLP-1 drug binds to and activates the GLP-1 receptor. The Wegovy label says semaglutide binds to that receptor and switches it on.
The same label says GLP-1 is a natural regulator of appetite and calorie intake. Its receptor is found in several brain areas that control appetite. Tirzepatide (Zepbound) is a GIP receptor and GLP-1 receptor agonist.
A 2024 JAMA review sorts obesity drugs by how they act. It says liraglutide, semaglutide and tirzepatide copy hormones from the gut and pancreas. It calls them hormone-based medicines. It puts phentermine-topiramate in a different group. Those drugs act in the brain to control appetite.
Sources: Wegovy FDA label; Zepbound FDA label; JAMA 2024 review
Phentermine vs semaglutide vs tirzepatide, side by side
Phentermine differs from the GLP-1 drugs in drug group and in how it acts. Its label also limits it to a few weeks. It lists it as a Schedule IV controlled substance. The table sets out what the labels and the JAMA review say.
| Point | Phentermine | Semaglutide | Tirzepatide |
|---|---|---|---|
| Drug group | Sympathomimetic amine, with activity similar to amphetamine | GLP-1 receptor agonist | GIP receptor and GLP-1 receptor agonist |
| How the review groups it | Phentermine-topiramate: centrally acting, regulates appetite in the brain | Nutrient-stimulated hormone-based medicine | Nutrient-stimulated hormone-based medicine |
| Label rule on combining | Not recommended with other drugs for weight loss | Wegovy: not recommended with any other GLP-1 receptor agonist | Not covered in the sources here |
| Pooled weight loss in the JAMA review | Phentermine alone: not given. Phentermine-topiramate: 8.0% | 11.4% | 12.4% (15 mg) |
Disclaimer: the 15 mg figure is a trial dose reported in the review, not a recommendation. Dose decisions belong with a licensed clinician.
Sources: Phentermine FDA label; Wegovy FDA label; Zepbound FDA label; JAMA 2024 review
Does phentermine work as well as Ozempic?
No head-to-head trial was found, so the numbers come from separate studies. The phentermine label says people on the drug lost only a fraction of a pound a week more than people on placebo.
The 2024 JAMA review pooled these figures for greater weight loss:
- Phentermine-topiramate: 8.0% (5 trials, 3,407 participants)
- Semaglutide: 11.4% (5 trials, 4,421 participants)
- Tirzepatide 15 mg: 12.4% (6 trials, 1,972 participants)
Disclaimer: these are trial results and a trial dose from a review, not a recommendation. Dose decisions belong with a licensed clinician.
There is no figure here for phentermine alone. Ozempic and Wegovy both contain semaglutide; see Wegovy vs Ozempic for how they differ.
A 2026 review for the American College of Physicians compared the benefits and harms of obesity drugs. It says semaglutide and tirzepatide showed the most favorable results across outcomes. For more on those two, see tirzepatide vs semaglutide.
Sources: Phentermine FDA label; JAMA 2024 review; Ann Intern Med 2026 living review
Phentermine alone vs phentermine-topiramate
They are different drugs. Phentermine-topiramate adds a second medicine, topiramate. The 8.0% figure above is for that combination only.
Phentermine alone, under the label used here, is for a few weeks of use on its own. Pages that quote the combination's weight loss for plain phentermine mix up two different products.
Sources: JAMA 2024 review; Phentermine FDA label
Safety points on the phentermine label
The label's main safety points are its controlled status and the heart. It is Schedule IV, and it lists a history of cardiovascular disease.
The phentermine label lists a history of cardiovascular disease. Its examples include stroke, heart failure, heart rhythm problems (arrhythmias), coronary artery disease and uncontrolled high blood pressure.
No source here compares the safety of phentermine and semaglutide directly. For GLP-1 side effects, see our GLP-1 side effects guide.
Sources: Phentermine FDA label
Can phentermine and a GLP-1 be taken together?
The phentermine label says it is not recommended with other weight loss drugs. It says the safety and benefit of such combinations are not established. No trial of phentermine with semaglutide or tirzepatide was found.
The Wegovy label has its own rule. It says Wegovy is not recommended with other semaglutide products or any other GLP-1 drug. That rule is about GLP-1 drugs. It does not mention phentermine.
For other options in this group, see our Ozempic alternatives roundup, and for label dose steps, the semaglutide dosage chart and tirzepatide dosage guide.
Sources: Phentermine FDA label; Wegovy FDA label
Phentermine and GLP-1 questions
Is phentermine a GLP-1?+
No. The phentermine FDA label calls it a sympathomimetic amine. Its action is similar to amphetamine. The Wegovy label says semaglutide acts on the GLP-1 receptor. A 2024 JAMA review puts the two in different drug groups.
Is phentermine better than GLP-1?+
No head-to-head trial was found, so there is no direct answer. The phentermine label says the extra weight loss over placebo was only a fraction of a pound a week. A 2026 review for the American College of Physicians says semaglutide and tirzepatide showed the most favorable results across outcomes.
Does phentermine work as well as Ozempic?+
No head-to-head trial was found. Ozempic is semaglutide. In a 2024 JAMA review, semaglutide was linked to 11.4% greater weight loss across 5 trials. The review gives no figure for phentermine alone.
Is phentermine as good as Ozempic?+
The sources here cannot say, because the two were not tested side by side. The JAMA review gives 8.0% for phentermine-topiramate, a combination pill, and 11.4% for semaglutide. Those figures come from different trials, and neither is for phentermine alone.
What is safer, phentermine or semaglutide?+
No study here compares their safety directly. The phentermine label calls it a Schedule IV controlled substance. It is for short-term use of a few weeks. The label also lists a history of heart and blood vessel disease. Safety for your own health is a question for a licensed clinician.
What organ is phentermine hard on?+
The label points used here are about the heart and blood vessels. It lists a history of cardiovascular disease. Its examples include stroke, heart failure, heart rhythm problems (arrhythmias), coronary artery disease and uncontrolled high blood pressure.
Why do doctors not like phentermine?+
We cannot speak for doctors. The label gives the facts that bear on it. Phentermine is a Schedule IV controlled substance with action similar to amphetamine. It is for a few weeks only. Its extra weight loss over placebo was a fraction of a pound a week.
Can you lose 20 pounds in a month on phentermine?+
The phentermine label gives no such figure. It says people on the drug lost only a fraction of a pound a week more than people on placebo.
Sources: Phentermine FDA label; Wegovy FDA label; JAMA 2024 review; Ann Intern Med 2026 living review
Related GLP-1 guides
This guide is for educational purposes only and is not medical advice. It describes what FDA labels and published reviews report about phentermine and GLP-1 drugs. Questions about your own medicines belong with a licensed clinician.